Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment Full enrollment expected by Q2 2026 with plans to seek early approval at that time ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results